This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Zimmer Holdings Names Paul Bisaro To Board Of Directors

WARSAW, Ind., Dec. 16, 2013 /PRNewswire/ -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global leader in musculoskeletal care, today announced that Paul Bisaro, Chairman, President and Chief Executive Officer of Actavis plc (NYSE: ACT), has been appointed to its Board of Directors.

Mr. Bisaro has served as President and Chief Executive Officer and a member of the board of directors of Actavis (formerly Watson Pharmaceuticals, Inc.), a global, integrated specialty pharmaceutical company, since 2007.  He was appointed Chairman in October 2013 following the company's acquisition of Warner Chilcott plc.  During his tenure as CEO, the company's revenues have grown from approximately $2 billion to anticipated pro forma revenue of approximately $11 billion in 2013.  Actavis has global headquarters in Dublin, Ireland and U.S. administrative headquarters in Parsippany, New Jersey.  The company markets products in more than 60 countries and has more than 30 manufacturing and distribution facilities around the world.  In driving Actavis' evolution, Mr. Bisaro has championed six significant acquisitions, most recently completing the acquisition of Warner Chilcott, which has transformed the Company's U.S. brands business into the leadership position in Women's Health and the third largest specialty pharmaceutical business in the United States.  Combined, Actavis and Warner Chilcott have a portfolio of more than 25 brand pharmaceutical products in various stages of development, with approximately 16 in Women's Health. 

" Paul Bisaro brings a wealth of experience leading highly respected global pharmaceutical companies and a strong track record of growth and international expansion; his perspective as a healthcare industry veteran will be instrumental to Zimmer's Board of Directors," said Larry Glasscock, Chairman of the Board.  "We are delighted that Paul has agreed to join the Board and we look forward to his contribution in guiding Zimmer's long-term strategic vision."  

Prior to joining Actavis, Mr. Bisaro served as President, Chief Operating Officer and a member of the board of directors at Barr Pharmaceuticals, Inc. from 1999 to 2007, and as General Counsel from 1992 to 1999.  Prior to joining Barr, Mr. Bisaro was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds, from 1989 to 1992. 

Mr. Bisaro holds a Juris Doctor from The Catholic University of America in Washington, D.C. and earned his undergraduate degree in General Studies at the University of Michigan.  He currently serves on the Board of Visitors of The Catholic University of America, Columbus School of Law.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products.  Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries.  Zimmer's 2012 sales were approximately $4.5 billion.  The Company is supported by the efforts of more than 9,000 employees worldwide.

SOURCE Zimmer Holdings, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs